The global Toxic Epidermal Neurolysis Drug market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Antibiotics Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Toxic Epidermal Neurolysis Drug include Pfizer, Novartis, Sanofi, Merck and Co, Sun pharma, Abbott laboratories, Johnson & Johnson, Teva pharmaceuticals and Viatris, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people.
This report aims to provide a comprehensive presentation of the global market for Toxic Epidermal Neurolysis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Toxic Epidermal Neurolysis Drug. This report contains market size and forecasts of Toxic Epidermal Neurolysis Drug in global, including the following market information:
Global Toxic Epidermal Neurolysis Drug Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Toxic Epidermal Neurolysis Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Toxic Epidermal Neurolysis Drug Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Toxic Epidermal Neurolysis Drug Market Segment Percentages, by Type, 2023 (%)
Antibiotics
Corticosteroids
Intravenous Immunoglobulins
Global Toxic Epidermal Neurolysis Drug Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Toxic Epidermal Neurolysis Drug Market Segment Percentages, by Application, 2023 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Toxic Epidermal Neurolysis Drug Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Toxic Epidermal Neurolysis Drug Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Toxic Epidermal Neurolysis Drug revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Toxic Epidermal Neurolysis Drug revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Sanofi
Merck and Co
Sun pharma
Abbott laboratories
Johnson & Johnson
Teva pharmaceuticals
Viatris
Outline of Major Chapters:
Chapter 1: Introduces the definition of Toxic Epidermal Neurolysis Drug, market overview.
Chapter 2: Global Toxic Epidermal Neurolysis Drug market size in revenue.
Chapter 3: Detailed analysis of Toxic Epidermal Neurolysis Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Toxic Epidermal Neurolysis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Toxic Epidermal Neurolysis Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Toxic Epidermal Neurolysis Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Toxic Epidermal Neurolysis Drug Overall Market Size
2.1 Global Toxic Epidermal Neurolysis Drug Market Size: 2023 VS 2030
2.2 Global Toxic Epidermal Neurolysis Drug Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Toxic Epidermal Neurolysis Drug Players in Global Market
3.2 Top Global Toxic Epidermal Neurolysis Drug Companies Ranked by Revenue
3.3 Global Toxic Epidermal Neurolysis Drug Revenue by Companies
3.4 Top 3 and Top 5 Toxic Epidermal Neurolysis Drug Companies in Global Market, by Revenue in 2023
3.5 Global Companies Toxic Epidermal Neurolysis Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Toxic Epidermal Neurolysis Drug Players in Global Market
3.6.1 List of Global Tier 1 Toxic Epidermal Neurolysis Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Toxic Epidermal Neurolysis Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Toxic Epidermal Neurolysis Drug Market Size Markets, 2023 & 2030
4.1.2 Antibiotics
4.1.3 Corticosteroids
4.1.4 Intravenous Immunoglobulins
4.2 By Type - Global Toxic Epidermal Neurolysis Drug Revenue & Forecasts
4.2.1 By Type - Global Toxic Epidermal Neurolysis Drug Revenue, 2019-2024
4.2.2 By Type - Global Toxic Epidermal Neurolysis Drug Revenue, 2025-2030
4.2.3 By Type - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Toxic Epidermal Neurolysis Drug Market Size, 2023 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.2 By Application - Global Toxic Epidermal Neurolysis Drug Revenue & Forecasts
5.2.1 By Application - Global Toxic Epidermal Neurolysis Drug Revenue, 2019-2024
5.2.2 By Application - Global Toxic Epidermal Neurolysis Drug Revenue, 2025-2030
5.2.3 By Application - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Toxic Epidermal Neurolysis Drug Market Size, 2023 & 2030
6.2 By Region - Global Toxic Epidermal Neurolysis Drug Revenue & Forecasts
6.2.1 By Region - Global Toxic Epidermal Neurolysis Drug Revenue, 2019-2024
6.2.2 By Region - Global Toxic Epidermal Neurolysis Drug Revenue, 2025-2030
6.2.3 By Region - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Toxic Epidermal Neurolysis Drug Revenue, 2019-2030
6.3.2 US Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.3.3 Canada Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.3.4 Mexico Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Toxic Epidermal Neurolysis Drug Revenue, 2019-2030
6.4.2 Germany Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.3 France Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.4 U.K. Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.5 Italy Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.6 Russia Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.7 Nordic Countries Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.4.8 Benelux Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Toxic Epidermal Neurolysis Drug Revenue, 2019-2030
6.5.2 China Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.5.3 Japan Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.5.4 South Korea Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.5.5 Southeast Asia Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.5.6 India Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Toxic Epidermal Neurolysis Drug Revenue, 2019-2030
6.6.2 Brazil Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.6.3 Argentina Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Toxic Epidermal Neurolysis Drug Revenue, 2019-2030
6.7.2 Turkey Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.7.3 Israel Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.7.4 Saudi Arabia Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
6.7.5 UAE Toxic Epidermal Neurolysis Drug Market Size, 2019-2030
7 Toxic Epidermal Neurolysis Drug Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Toxic Epidermal Neurolysis Drug Major Product Offerings
7.1.4 Pfizer Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.1.5 Pfizer Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Toxic Epidermal Neurolysis Drug Major Product Offerings
7.2.4 Novartis Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.2.5 Novartis Key News & Latest Developments
7.3 Sanofi
7.3.1 Sanofi Company Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Toxic Epidermal Neurolysis Drug Major Product Offerings
7.3.4 Sanofi Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.3.5 Sanofi Key News & Latest Developments
7.4 Merck and Co
7.4.1 Merck and Co Company Summary
7.4.2 Merck and Co Business Overview
7.4.3 Merck and Co Toxic Epidermal Neurolysis Drug Major Product Offerings
7.4.4 Merck and Co Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.4.5 Merck and Co Key News & Latest Developments
7.5 Sun pharma
7.5.1 Sun pharma Company Summary
7.5.2 Sun pharma Business Overview
7.5.3 Sun pharma Toxic Epidermal Neurolysis Drug Major Product Offerings
7.5.4 Sun pharma Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.5.5 Sun pharma Key News & Latest Developments
7.6 Abbott laboratories
7.6.1 Abbott laboratories Company Summary
7.6.2 Abbott laboratories Business Overview
7.6.3 Abbott laboratories Toxic Epidermal Neurolysis Drug Major Product Offerings
7.6.4 Abbott laboratories Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.6.5 Abbott laboratories Key News & Latest Developments
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Company Summary
7.7.2 Johnson & Johnson Business Overview
7.7.3 Johnson & Johnson Toxic Epidermal Neurolysis Drug Major Product Offerings
7.7.4 Johnson & Johnson Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.7.5 Johnson & Johnson Key News & Latest Developments
7.8 Teva pharmaceuticals
7.8.1 Teva pharmaceuticals Company Summary
7.8.2 Teva pharmaceuticals Business Overview
7.8.3 Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Major Product Offerings
7.8.4 Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.8.5 Teva pharmaceuticals Key News & Latest Developments
7.9 Viatris
7.9.1 Viatris Company Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Toxic Epidermal Neurolysis Drug Major Product Offerings
7.9.4 Viatris Toxic Epidermal Neurolysis Drug Revenue in Global Market (2019-2024)
7.9.5 Viatris Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Toxic Epidermal Neurolysis Drug Market Opportunities & Trends in Global Market
Table 2. Toxic Epidermal Neurolysis Drug Market Drivers in Global Market
Table 3. Toxic Epidermal Neurolysis Drug Market Restraints in Global Market
Table 4. Key Players of Toxic Epidermal Neurolysis Drug in Global Market
Table 5. Top Toxic Epidermal Neurolysis Drug Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Toxic Epidermal Neurolysis Drug Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Toxic Epidermal Neurolysis Drug Revenue Share by Companies, 2019-2024
Table 8. Global Companies Toxic Epidermal Neurolysis Drug Product Type
Table 9. List of Global Tier 1 Toxic Epidermal Neurolysis Drug Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Toxic Epidermal Neurolysis Drug Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Toxic Epidermal Neurolysis Drug Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Toxic Epidermal Neurolysis Drug Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Toxic Epidermal Neurolysis Drug Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Toxic Epidermal Neurolysis Drug Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Toxic Epidermal Neurolysis Drug Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Toxic Epidermal Neurolysis Drug Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2025-2030
Table 30. Pfizer Company Summary
Table 31. Pfizer Toxic Epidermal Neurolysis Drug Product Offerings
Table 32. Pfizer Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 33. Pfizer Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Toxic Epidermal Neurolysis Drug Product Offerings
Table 36. Novartis Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 37. Novartis Key News & Latest Developments
Table 38. Sanofi Company Summary
Table 39. Sanofi Toxic Epidermal Neurolysis Drug Product Offerings
Table 40. Sanofi Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 41. Sanofi Key News & Latest Developments
Table 42. Merck and Co Company Summary
Table 43. Merck and Co Toxic Epidermal Neurolysis Drug Product Offerings
Table 44. Merck and Co Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 45. Merck and Co Key News & Latest Developments
Table 46. Sun pharma Company Summary
Table 47. Sun pharma Toxic Epidermal Neurolysis Drug Product Offerings
Table 48. Sun pharma Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 49. Sun pharma Key News & Latest Developments
Table 50. Abbott laboratories Company Summary
Table 51. Abbott laboratories Toxic Epidermal Neurolysis Drug Product Offerings
Table 52. Abbott laboratories Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 53. Abbott laboratories Key News & Latest Developments
Table 54. Johnson & Johnson Company Summary
Table 55. Johnson & Johnson Toxic Epidermal Neurolysis Drug Product Offerings
Table 56. Johnson & Johnson Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 57. Johnson & Johnson Key News & Latest Developments
Table 58. Teva pharmaceuticals Company Summary
Table 59. Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Product Offerings
Table 60. Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 61. Teva pharmaceuticals Key News & Latest Developments
Table 62. Viatris Company Summary
Table 63. Viatris Toxic Epidermal Neurolysis Drug Product Offerings
Table 64. Viatris Toxic Epidermal Neurolysis Drug Revenue (US$, Mn) & (2019-2024)
Table 65. Viatris Key News & Latest Developments
List of Figures
Figure 1. Toxic Epidermal Neurolysis Drug Segment by Type in 2023
Figure 2. Toxic Epidermal Neurolysis Drug Segment by Application in 2023
Figure 3. Global Toxic Epidermal Neurolysis Drug Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Toxic Epidermal Neurolysis Drug Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Toxic Epidermal Neurolysis Drug Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Toxic Epidermal Neurolysis Drug Revenue in 2023
Figure 8. By Type - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 9. By Application - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 10. By Type - Global Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 12. By Application - Global Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 14. By Region - Global Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 15. By Country - North America Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 16. US Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 20. Germany Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 21. France Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 28. China Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 32. India Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 34. Brazil Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Toxic Epidermal Neurolysis Drug Revenue Market Share, 2019-2030
Figure 37. Turkey Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Toxic Epidermal Neurolysis Drug Revenue, (US$, Mn), 2019-2030
Figure 41. Pfizer Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Novartis Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Sanofi Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Merck and Co Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Sun pharma Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Abbott laboratories Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Johnson & Johnson Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Viatris Toxic Epidermal Neurolysis Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
